Clinical Trial Update: A Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1) [Phase 1]

View source ↗

Summary

A clinical trial update indicates that the Phase 1 study of DCR-PH1 for Primary Hyperoxaluria Type 1 has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperoxaluria Type

Drugs mentioned

• DCR-PH1 (DCR-PH1)

Snippet

Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Conditions: Primary Hyperoxaluria Type 1 | Phase 1 | Status: TERMINATED